Innovation at Penn
Browse Penn-owned technologies available for licensing.
Search Results - alba+rodriguez-garcia
CAR T cell therapy for the treatment of ovarian cancer and other gynecologic malignancies
Anti-Mullerian inhibiting substance type II receptor (MISRII) specific CAR T cell therapy for the targeted, safe treatment of ovarian cancer. Technology Overview: Ovarian cancer is the 5th leading cause of cancer-related deaths in women and is the most lethal of all gynecologic malignancies with an overall 5-year survival rate of 46%. The Müllerian...
Therapeutics & Vaccines
© 2021. All Rights Reserved. Powered by